CD274 and cervical carcinoma: In conclusion, this systematic review reveals that while pembrolizumab holds significant promise as a treatment for recurrent and metastatic cervical cancer, especially in PD-L1-positive populations, its real-world efficacy might be optimized through tailored combination therapies and more stratified patient selection.